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PTEN, a tumor suppressor gene, has been identified as an overgrowth susceptibility gene causing 
Cowden syndrome. Cowden syndrome is characterized by an increased risk for breast cancer and 
other malignancies, mucocutaneous lesions, and macrocephaly. Macrocephaly is a hallmark of 
Cowden syndrome, is considered a major criterion for the clinical diagnosis, and is present in an 
estimated 80% of individuals diagnosed with Cowden syndrome. However, it is unknown what 
percentage of genetic counselors routinely measure head circumference when evaluating patients 
for hereditary cancer assessment. This study queried National Society of Genetic Counselors 
(NSGC) members about current practices and opinions regarding head circumference 
measurement. A questionnaire was dispersed electronically to all members of NSGC, and those 
who have practiced cancer genetic counseling in the last six months were eligible to respond. 
The data from 216 surveys was analyzed using descriptive statistics and qualitative methods 
including thematic analysis. Eighty-four percent of genetic counselors are not measuring head 
circumference on every patient presenting for hereditary cancer assessment, nor those who are 
specifically presenting for hereditary breast cancer assessment. Thematic analysis revealed these 
individuals feel head circumference measurement should not be standard in a cancer assessment, 
but reserved for those who are suspicious of Cowden syndrome based on personal or family 
history. Additionally, some genetic counselors expressed they have not received appropriate 
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training in head circumference measurement. However, the 29% of genetic counselors who 
believe head circumference should routinely be measured felt it is a quick and easy measurement 
that is helpful in assessment and is good clinical practice. Thematic analysis also revealed mixed 
responses about the value of head circumference measurement with the increasing use of next 
generation sequencing panels. 
 Although macrocephaly is a major diagnostic criterion for Cowden syndrome, there have 
been diverse outcomes on the exact incidence, ranging from 40-100%. Identification of Cowden 
syndrome has significant public health implications.  Because Cowden syndrome is associated 
with increased lifetime risks of cancer of multiple organ sites, and because increased screening 
and consideration of risk-reducing surgery, it is important that health care professionals identify 
cases of Cowden syndrome in their patient population. 
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1.0  INTRODUCTION 
Cowden syndrome is an autosomal dominant condition that affects approximately 1/200,000 
individuals, however, this is most likely an underestimate due to the variability in expression of 
symptoms. It is caused by germline mutations in the PTEN tumor suppressor gene. Individuals 
with Cowden syndrome are at an exceptionally high risk for breast cancer, mucocutaneous 
lesions, and a predisposition to hamartomas.1 A clinical diagnosis is made from a combination of 
mucocutaneous features, major criteria, and/or minor criteria. One of the clinical hallmarks and 
major diagnostic criterion of Cowden syndrome is macrocephaly, which is defined as a head 
circumference greater than or equal to the 97th percentile (58 centimeters for adult women and 60 
centimeters for adult men).2 Mucocutaneous lesions in the form of trichilemmomas, acral 
keratosis, and papillomatous lesions also contribute to the major diagnostic criteria. Another 
major criterion almost exclusively seen in Cowden syndrome is adult-onset Lhermitte-Duclos 
disease. Other major criteria are breast carcinoma, non-medullary thyroid carcinoma (especially 
follicular), and endometrial carcinoma. Several minor criteria are also concerning for Cowden 
syndrome, and all criteria are discussed in detail below. 
Due to the variability in expression, individuals, particularly women, who might benefit 
from PTEN gene testing could be missed if head circumference is not measured. Occipital-
frontal head circumference is a physical feature that is relatively easy to measure accurately and 
reproducibly in routine clinical care. However, we hypothesize that the clinical approach to an 
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individual at high risk for breast cancer often does not include head circumference measurement. 
Practices of genetic counselors regarding head circumference measurement in a cancer genetic 
counseling setting has not yet been assessed in the literature. It seems reasonable that cancer 
genetic counselors would be the health care professionals to implement the measurement due to 
their experience in cancer risk assessment based on personal and family medical histories. 
Because of this, assessing the attitudes of genetic counselors towards head circumference 
measurement may give a better understanding of the perceived benefits and limitations of head 
circumference measurement. Routine screening for Cowden syndrome clinical features could 
increase detection with substantial implications for a patient’s care. 
1.1 BACKGROUND AND SIGNIFICANCE 
1.1.1 Head Circumference 
1.1.1.1 Birth to 18 years 
Head circumference in children has been well studied and established since 1948, but the first 
graphs providing head circumference past the first few years of life were not published until 
1968. These graphs were prepared by using the world data obtained since 1948, and the grand 
means and standard deviations for age and sex were calculated from the pooled variances.3 The 
participants were stated or considered to have been full term infants and older children were 
physically and mentally well. 
Two thirds of total head growth from birth to adulthood occurs within the first two years 
of life, and less than two percent of total head circumference growth occurs after the age of 18 
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years.4 Head growth in boys is slightly more rapid in the first two years of life and approximately 
0.9 centimeters larger than girls overall.3 There is no appreciable difference in head 
circumference for race in either sex.  Nellhaus et al. concluded that head circumference 
measurement should be as much a part of a physical examination as obtaining the height and 
weight. Nellhaus et al. also noted that head circumference measurements graphed routinely may 
lead to an early diagnosis of certain conditions. 
A similar study was conducted 20 years later2 and reached the same conclusions as 
previously reported3. However, Roche et al. noted that the head circumference in their sample 
was larger from birth to six months and at older ages. Roche et al. concluded that this difference 
may have been due to the low socioeconomic status of the previous study, differences in the 
method of measurement, or the years in which the data was collected. To create a more uniform 
reference for head circumference, the World Health Organization (WHO) released head 
circumference growth charts in 2007 that are intended for international use.5 However, the 
standards are limited to age 5 years, causing a need for more standard charts beyond this age. 
1.1.1.2 Adulthood 
While investigating a child with an apparently isolated abnormal head circumference, the parents 
should also be measured since studies have shown that up to 50% of normal variation in head 
size is familial.6 However, until 1992, head circumference charts for adults past the age of 18 
years were non-existent. The first adult head circumference charts were published at this time 
using a British cohort.7 Bushby et al. concluded that height should be taken into account when 
graphing the head circumference of adults. They also noted that due to the later pubertal 
development of males, head circumference continues to grow into early adulthood which is not 
true for females. 
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 Head circumference appears to be a useful parameter for a variety of different reasons. It 
can be used when pediatricians search for familial syndromes with parental microcephaly or 
macrocephaly. Head circumference can also be a measurement for brain size and cognitive 
reserve that is associated with severity of impairment in Alzheimer’s disease.8 Graves et al. 
indicated that patients with probable Alzheimer’s disease who had smaller head circumference 
had lower scores on a global cognitive test than those with larger head circumference. The 
findings suggest that brain size may be important in determining reserve capacity. This could 
potentially modify the clinical presentation of that process. Other studies have found similar 
results and the research continues to improve in this area. 
 Head circumference in adults has also been identified as a marker for genetic syndromes 
that may not be present in childhood or adolescence. Genetic syndromes are often defined by 
different physical findings that are frequently seen in individuals with a certain condition. It has 
been generally accepted that the definition of normocephalic includes those that are within two 
standard deviations of the mean.2; 3 Any measurement below two standard deviations is 
considered microcephalic and above is considered macrocephalic. This corresponds to below the 
third percentile and above the 97th percentile, respectively.  The most well-known genetic 
syndrome associated with macrocephaly is Cowden syndrome, a PTEN hamartoma tumor 
syndrome, which is associated with an increased risk for breast cancer, as well as other cancers 
and skin manifestations. 
1.1.1.3 Macrocephaly 
Macrocephaly is a common cause of genetic evaluation, especially when associated with 
developmental delay or autism spectrum disorders. There are various genetic syndromes 
associated with macrocephaly, including Neurofibromatosis 1 (NF1), Fragile X syndrome, Sotos 
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syndrome, Weaver syndrome, Simpson-Golabi-Behmel syndrome, and metabolic disorders.9 
Evaluation for macrocephaly associated with a developmental disorder often includes a physical 
examination, brain CT or MRI, chromosome analysis including karyotype and/or microarray, 
Fragile X testing, and metabolic screening. PTEN screening has also been suggested in the case 
of familial macrocephaly over 3 standard deviations when the first screening methods are 
negative. 
1.1.2 Features of Cowden Syndrome  
Cowden syndrome is considered to be part of the spectrum of PTEN hamartoma tumor 
syndromes (PHTS), which also includes Bannayan-Riley-Ruvalcaba (BRRS), Proteus, and 
Proteus-like syndromes.10 It was first described in 1963 and the prevalence of PHTS is estimated 
to be about 1 in 200,000, but this is suspected to be an underestimate due to the variability in 
expression and the subtlety of skin findings. Cowden syndrome is inherited in an autosomal 
dominant fashion. Cowden syndrome is associated with a high risk for benign and malignant 
tumors of the thyroid, breast, and endometrium. Renal cell carcinoma and colorectal carcinoma 
have also recently been shown at increased risk for individuals with PTEN mutations. Affected 
individuals usually present with macrocephaly and mucocutaneous lesions that usually present 
by the late twenties. More than 90% of individuals with Cowden syndrome have some clinical 
manifestation,11 and by the third decade of life, 99% of affected individuals develop the 
mucocutaneous lesions. There are several different features, both malignant and non-malignant,  
that are associated with Cowden syndrome that will be discussed. 
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1.1.2.1 Head Circumference 
In a clinical setting, there are no established guidelines that include head circumference 
measurement for individuals with breast cancer. It has been estimated that the current incidence 
of macrocephaly among women who meet the PHTS criteria to be at least 80%.10 Until recently, 
head circumference measurement had not been studied clinically to determine if it is a useful 
clinical feature for the diagnosis of Cowden syndrome. It appears that macrocephaly is in fact a 
useful feature contributing to the clinical diagnosis of Cowden syndrome, given its high 
sensitivity.12 However, the presence of macrocephaly alone will not identify all PTEN mutation 
carriers, even in a high risk population. Although this may be true, routine head circumference 
measurement offers a clinical advantage for identifying those with PHTS in high-risk breast 
cancer clinics.  
Macrocephaly is known to be associated with Cowden syndrome, but the reported 
frequencies very widely in the literature. The frequency was initially reported to be 40% in early 
reports, but has been found to be 80-100% in more recently published studies.13-15 It has been 
suggested that PTEN screening also be performed in the case of familial macrocephaly over three 
standard deviations when the first macrocephaly screening, such as physical examination, brain 
CT or MRI, or chromosome analysis is normal.16 
1.1.2.2 Malignant Findings 
The most common cancer associated with Cowden syndrome is breast cancer. The lifetime risk 
for women with Cowden syndrome is 25-50%,17-19 compared to the general population at 8-
12%.20 However, a more recent study that prospectively collected and followed families with a 
PTEN pathogenic variant revealed the lifetime risk to be 85%.21 The average age of diagnosis is 
usually between 38 and 46 years of age, which is ten years younger than women with sporadic 
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breast cancer. There have only been two reported cases of male breast cancer associated with 
Cowden syndrome13 and no reported cases in the largest cohort of patients with PTEN testing to 
date18. Cowden syndrome associated breast cancers, along with other hereditary breast cancers, 
are also more likely to be multifocal and bilateral compared to sporadic breast cancers. 
Endometrial cancer has been reported to be the second most common cancer in 
individuals with Cowden syndrome. The lifetime risk in women with Cowden syndrome has 
been estimated to be 19-28% at age 70 years,21 compared to the general population lifetime risk 
of 2.5%.18; 22 However, this evidence may be an under or overestimate for the following reasons: 
These studies did not censor endometrial cancer incidence rates for previous hysterectomy, 
causing an underestimation, and the studies contain ascertainment bias, leading to an 
overestimation. 
 The chance of developing non-medullary (follicular or papillary) thyroid cancer is 
approximately 3-10% in individuals with Cowden syndrome, compared to a lifetime risk of less 
than 1% in the general population.23 Papillary thyroid cancer accounts for 80-85% of the non-
medullary cancer in the general population, while follicular cancer accounts for only about 15%. 
Medullary thyroid cancer is not felt to be part of the syndrome. Among confirmed mutation 
carriers who develop thyroid cancer, both papillary, 56-60% risk, and follicular, 25-45% risk, 
have been reported.24 Follicular thyroid cancer appears to be over-represented in mutation 
carriers compared with the general population and may have greater value in predicting PTEN 
mutation status. 
 An increased risk for colon cancer has not historically been described in the Cowden 
syndrome tumor spectrum, however, recent studies have described a risk. These risks have 
ranged from 9-16%21; 25; 26 and the individuals were all under the age of 50 years. The risk for 
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other cancers, such a renal cell carcinoma and cutaneous melanoma, has also been suggested to 
be increased in Cowden syndrome. The lifetime risk for renal cell carcinoma is 35%, and the 
average age of onset is in the fourth decade of life.21 A lifetime risk for melanoma has recently 
been reported to be 6%21, suggesting it may be associated with Cowden syndrome. 
1.1.2.3 Non-malignant Findings 
Individuals with Cowden syndrome are also at an increased risk for benign hamartomatous 
overgrowth in a number of tissues. Historically it has been reported that a majority of individuals 
with Cowden syndrome have mucocutaneous manifestations, as high as 90-100%27, and was 
initially thought to be a primarily dermatological disease.20 One of the hallmark features of 
Cowden syndrome is trichilemmomas and is pathognomonic when 3 or more lesions are present. 
Multiple trichilemmomas are commonly observed on the face, especially on the eyes, mouth, 
nose, and forehead, and have also been found on the neck, axillae, and hands.26; 28; 29 
Trichilemmomas are clinically significant sign of Cowden syndrome when 3 or more are 
observed in an individual. However, some individuals have few and relatively insignificant skin 
manifestations, which could easily be overlooked on a primary exam. 
Other mucocutaneous lesions are also prevalent, such as oral papillomas, which are a 
major criterion and can be seen in abundance on the lips, tongue, buccal mucosa, and gingivae.20; 
23; 26; 30 It has been reported that 100% of individuals with Cowden syndrome will present with 
this finding by the second decade of life, and this manifestation is typically asymptomatic.20; 31 
Mucocutaneous neuromas (hamartoma of the peripheral nerve sheath), at least three present on 
the face or elsewhere on the body, should be counted as a major diagnostic feature of PHTS due 
to reports of more than half of individuals presented with this manifestation.20 Acral keratoses 
are located on the palmoplantar surfaces and dorsal hands/feet and are wart-like appearing 
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lesions.20; 22; 28; 32 They have been noted in both pediatric and adult populations with PTEN 
mutations but further studies are needed to determine the age of onset and penetrance.33-35 Penile 
pigmentation is a major criterion in males and has been found in 53% of males with PTEN 
mutations or a clinical diagnosis of Cowden syndrome.17; 36 
Benign thyroid disease, including goiter, nodules, and adenomas, has been estimated to 
affect 30-68% of adults and 2-14% of children with Cowden syndrome. 17; 36 Thyroid nodules 
occur at a range of lifetime frequencies, from 2-6% based on physical exam, 19-35% based on 
ultrasound, and 65% based on autopsy.37 Multinodular goiter is present in about 4% of the 
population38 and Hashimoto’s thyroiditis occurs in 2% of the population39. One study looked 
specifically at Hashimoto’s thyroiditis and reported a prevalence of 3-21% in individuals with 
PTEN mutations.18 However, no studies to date have looked at the likelihood of detecting PTEN 
mutations in individuals presenting only with benign thyroid disease. 
Benign breast disease is commonly seen in individuals with Cowden syndrome and 
presents with varying and often complex histologies. Benign breast disease includes all non-
malignant conditions of the breast, fibrocystic disease, intraductal papillomas, and 
fibroadenomas. Up to 60% of premenopausal women in the general population may develop 
fibrocystic breast disease14 and 50% of all breast biopsies are constituted as fibroadenomas33, 
making this the most common benign tumor of the breast. The reported frequencies of benign 
breast disease in women with Cowden syndrome are between 32-64%.18; 20; 40; 41 In a small study, 
the pathology of benign breast findings were analyzed34. Widespread and complex pathology 
was noted and the hamartomatous lesions were more diffuse and more often multifocal and 
bilateral than in patients without Cowden syndrome. 
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Polyps of the gastrointestinal tract have generally been said to affect about 40% of 
individuals with Cowden syndrome. However, this may be an underestimate due to the lessened 
frequency of asymptomatic individuals undergoing endoscopic surveillance.36 The polyps 
associated with Cowden syndrome are primarily hamartomatous, but there have been reports that 
include hyperplastic, inflammatory, juvenile, leiomyomatous, lipomatous, lymphoid, and 
neuromatous. It has been suggested that GI adenomas reported in individuals with Cowden 
syndrome are coincidental rather than related to the disease.10 
It is unclear whether uterine fibroids are seen at an increased frequency in women with 
Cowden syndrome, even though they are part of the minor diagnostic criteria.38 The general U.S. 
population risk for uterine fibroids by age 50 has been reported to be 70% for Caucasian women 
and 80% for African American women.42 It seems unlikely that the rate for uterine fibroids in 
women with Cowden syndrome is dramatically increased.20 
The precise estimate of the frequency of brain lesions in individuals with Cowden 
syndrome is not available since brain imaging is rarely done on asymptomatic individuals. Those 
with Cowden syndrome are known to be at an increased risk for Lhermitte-Duclos disease 
(dysplastic gangliocytoma of the cerebellum; LDD). Lhermitte-Duclos is a rare, slow growing, 
non-malignant hamartomatous brain lesion and is usually diagnosed in the second or third 
decade of life. The prevalence of LDD found in individuals undergoing clinical PTEN testing 
have been found to be 1.8%41, 6%18, and 15%26. MRI is the preferred diagnostic imaging 
modality and treatment is through surgical excision. LDD was first recognized to be associated 
with Cowden syndrome in 199140, and since then, 54 more cases have been identified, yet the 
frequency of LDD in individuals with Cowden syndrome is unknown28. 
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Hemangiomas have been seen at increased rates in a number of studies, compared to the 
general population risk of approximately 5-10%.10 Arteriovenous malformations (AVMs) seem 
to be less frequent since they have been noted in only a few case studies. These are both features 
of BRRS, which is known to be allelic to Cowden syndrome and shows that PTEN plays a role 
in regulating VEGF-regulated angiogenesis. 
 Developmental delay and mental retardation have been reported to be associated with 
PTEN mutations in Cowden syndrome, but limited data is available. The number of cases 
reported range from 12-20% in the literature.17; 19; 22 Because the rate of mental retardation in the 
general population is approximately 3%, it appears this should remain a criterion despite the 
need for additional data.10 
 A recent study17 consisting of 172 individuals with PTEN mutations, the largest single 
cohort with testing reported, assessed the frequencies of the clinical features of Cowden 
syndrome, and which features are most predictive of a mutation. The results are listed below and 
differ significantly than other reports in the literature. This study also led to the development of a 
mutation-prediction model that should be useful in clinical practice.  
► Mucocutaneous lesions (77%) 
- Trichilemmomas 
- Acral keratosis 
- Papillomatous papules 
► Thyroid cancer (7.6%) 
► Breast cancer (41% of females, 0% of males) 
► Gastrointestinal cancer (suggested increase) 
► Macrocephaly (84%) 
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► Genitourinary abnormalities 
- Uterine fibroids (26%) 
- Endometrial cancer (17%) 
- Renal cell carcinoma (suggested increase) 
*Note: given the overall young age of the cohort, and that additional cancers might be diagnosed 
at later ages, the study may underestimate the lifetime cancer risks. 
1.1.2.4 Diagnostic Criteria 
 Before the gene known to cause Cowden syndrome was elucidated in 1996, the 
International Cowden Consortium proposed a set of operational diagnostic criteria to ascertain 
Cowden syndrome families and to assign affected status within families. The first diagnostic 
criteria were initially proposed in 198334 and were later revised by the researches (the 
consortium) who mapped the gene locus43. These criteria have since been adopted by the 
National Comprehensive Cancer Network (NCCN), whose task is to present evidence based or 
expert consensus practice guidelines. Modifications to the original criteria have been proposed, 
including the addition of endometrial cancer as a major criterion11, renal cell carcinoma as a 
minor criterion44, and more recently, adult Lhermitte-Duclos disease be moved into the 
pathognomonic category. 
 A study has suggested that the specificity of the Consortium criteria are lower than 
previously estimated.17 Only 34% of participants meeting the Cowden syndrome diagnostic 
criteria had a detectable mutation, which is significantly lower than the 80% previously 
reported45. This suggests that the Consortium criteria are not as robust at identifying individuals 
with PTEN mutations as previously thought. 
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 The clinical diagnostic criterion differs from the genetic testing criteria and is listed 
here1: 
Major Criteria 
► Breast cancer 
► Endometrial cancer (epithelial) 
► Thyroid cancer (follicular) 
► >3 Gastrointestinal hamartomas (includes ganglioneuromas but excludes hyperplastic 
polyps) 
► Lhermitte-Duclos disease (adult) 
► Macrocephaly (>97th percentile: 58cm for females, 60cm for males) 
► Macular pigmentation of the glans penis 
► Multiple mucocutaneous lesions (any of the following): 
- >3 trichilemmomas (at least one biopsy proven) 
- >3 palmoplantar keratotic pits and/or acral hyperkeratotic papules 
- >3 mucocutaneous neuromas 
- >3 oral papillomas (particularly on tongue or gingiva) OR biopsy proven OR 
dermatologist diganosed 
Minor Criteria 
► Autism spectrum disorder 
► Colon cancer 
► >3 esophageal glycogenic acanthuses 
► >3 lipomas 
► Mental retardation (IQ <75) 
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► Renal cell carcinoma 
► Testicular lipomatosis 
► Thyroid cancer (papillary or follicular variant of papillary) 
► Structural thyroid lesions (adenoma, multinodular goiter, etc) 
► Vascular anomalies (includes multiple intracranial developmental venous anomalies) 
Operational diagnosis in an individual (either of the following): 
1. Three or more major criteria, but one must include macrocephaly, Lhermitte-Duclos 
disease, or gastrointestinal hamartomas; or 
2. Two major and three minor criteria 
Operational diagnosis in a family where one individual meets revised PTEN hamartoma tumor 
syndrome clinical diagnostic criteria or has a PTEN mutation: 
1. Any two major criteria with or without minor criteria; or 
2. One major and two minor criteria; or 
3. Three minor criteria 
1.1.3 Genetics of Cowden Syndrome 
Cowden syndrome is caused by germline mutations in the PTEN (phosphatase and tensin 
homolog on chromosome 10) tumor suppressor gene located at 10q23.3.43 It is a dual specificity 
phosphatase with multiple and incompletely understood roles in cellular regulation.46 As a lipid 
phosphatase, PTEN is known to signal down the PI3K/Akt pathway to cause G1 cell cycle arrest 
and apoptosis. It has also been shown to regulate cell-survival pathways, such as the mitogen-
activated kinase (MAPK) pathway. PTEN mutations were first reported in individuals with 
Cowden syndrome in 1997.32 
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 Germline mutations in PTEN have also been associated with Bannayan-Riley-Ruvalcaba 
syndrome (BRRS), Proteus and Proteus-like syndrome, adult Lhermitte-Duclos disease, and 
autism-like disorders associated with macrocephaly. The penetrance of Cowden syndrome is 
thought to be nearly complete and approaches 90% penetrance by age 20 years.20 These figures 
are based on evidence from older studies that predated the development of the Consortium 
diagnostic criteria, so accurate penetrance estimates using the criteria are not available. 
 Although germline mutations in PTEN are generally reported to be found in about 80% of 
individuals with Cowden syndrome, detection rates using DNA sequencing have ranged from 
11-80% in individuals who have met the Consortium criteria.10 More recently in a much larger 
cohort, PTEN mutations have been found in 30-35% of patients meeting the diagnostic criteria.17 
This same study also concluded that 37% of individuals with mutations did not meet diagnostic 
criteria for Cowden syndrome or BRRS. More recent studies have been testing individuals with 
no detected mutations in PTEN to determine if there is a deletion or rearrangement of the gene. 
One study examined 95 individuals and found no evidence of large gene deletions or 
rearrangements.47 However, in another report, 80 unrelated individuals clinically diagnosed with 
Cowden syndrome but negative for a PTEN mutation were tested, and four individuals, or five 
percent, were found to have deletions.48 
 Because Cowden syndrome is rare and the diagnosis is difficult due to highly variable 
expressivity, data regarding genotype-phenotype correlations are limited and mostly based on a 
collection of case series. Most studies have failed to demonstrate a consistent genotype-
phenotype correlation, but all have found an increased risk for associated cancers.45; 49-51 
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1.1.3.1 Genetic Testing 
The National Comprehensive Cancer Network (NCCN) has used the Consortium criteria to serve 
as a basis for the list of PTEN mutation testing criteria which is included in the NCCN 
guidelines. Based on the literature and expert consensus, the panel recently revised the list of 
criteria associated with Cowden syndrome as well as the combinations of criteria that establish 
which individuals are candidates for PTEN mutation testing. The following is that criteria: 
► Individual from a family with a known PTEN mutation 
► Individual meeting clinical diagnostic criteria for Cowden syndrome/PHTS 
► Individual with a personal history of: 
- Bannayan-Riley-Ruvalcaba syndrome (BRRS) or 
- Adult Lhermitte-Duclos disease (cerebellar tumors) or 
- Autism spectrum disorder and macrocephaly or 
- Two or more biopsy-proven trichilemmomas or 
- Two or more major criteria (one must be macrocephaly) or 
- Three major criteria, without macrocephaly or 
- One major and >3 minor criteria or 
- >4 minor criteria 
► At-risk individuals with a relative with a clinical diagnosis of Cowden syndrome/PHTS 
or BRRS for whom testing has not been performed 
- The at-risk individual must have the following: 
 Any one major criterion or 
 Two minor criteria 
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As mentioned previously, Cowden syndrome is known to have wide variability in the 
clinical presentation between individuals, even within the same family. Because of this, it can be 
difficult to determine which individuals are appropriate candidates for PTEN genetic testing. It 
has been suggested that individuals meeting or coming close to meeting the Consortium 
diagnostic criteria should be tested.10  All individuals with Lhermitte-Duclos disease or multiple 
trichilemmomas should be tested, and those with macrocephaly, along with other significant 
Cowden syndrome findings, are also appropriate candidates. It is unclear, however, how much 
weight the minor criteria should be given since several of the criteria are common in the general 
population, and the dermatologic features may also be less obvious than implied in the literature. 
 There are also a number of studies that have suggested that individuals with features of 
Cowden syndrome should not be tested for PTEN mutations. These would include isolated cases 
of early onset breast cancer52, BRCA-negative familial breast cancer53, and isolated cases of 
endometrial cancer54. Testing may also not be of value to families with no signs of Cowden 
syndrome, other than breast and thyroid cancers and breast and brain cancers in the same 
individual or family41, and women with double primary cancers55.  
1.1.3.2 Cancer Gene Panels 
New genetic testing panels use next-generation sequencing that are intended for individuals who 
have tested negative for high penetrance genes and for those whose family history is suggestive 
of more than one cancer syndrome. The testing laboratories include somewhat different, but 
often overlapping, genes, and included in most of these panels is PTEN. The recent Supreme 
Court decision in June 2013 has allowed all testing companies to include BRCA1/2 in their 
panels.56 This decision has enabled companies to offer panels with more cancer predisposing 
genes, as well as reduce the cost of the panel. It has been suggested that multiplex panels will be 
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both clinically useful and cost-effective for patients with near-equivalent risks for Hereditary 
Breast and Ovarian Cancer (HBOC) syndrome and PHTS or other conditions.57 It has also been 
suggested that these panels should only be ordered in consultation with a cancer genetics 
professional due to the complexity and limited data available regarding their clinical utility. 
Table 1 shows that there are several advantages and disadvantages to panel testing.58 
Table 1. Advantages and disadvantages of panel testing 
Advantages Disadvantages 
Greater sensitivity for assessing cancer risks Insurance coverage still in question Limited data on risks for less penetrant genes 
Cost-effective for some patients (just about the 
same as an individual gene) 
Difficulty interpreting risks when mutations in 
more than one gene occur 
Explanation of negative results can be more 
confusing for patients 
Extend genetic risk assessment to a wider 
population 
Lack of established management guidelines for 
lower penetrance genes 
Difficulty defining the target population for 
testing 
Determine who is at risk for highly penetrant 
cancers, moderate risk due to lower penetrance, 
or average population risk 
Increased chance of detecting a variant of 
unknown significance (limited information 
available on impact of VUS on risk) 
Broaden number of gene targets used to assess 
risk 
More complex results – false positive rates 
increase with increasing number of tests and 
when testing low risk population 
1.1.4 Management and Treatment 
Management guidelines for individuals with Cowden syndrome have been adopted by the NCCN 
and should be followed for all individuals with germline PTEN mutations. Individuals who have 
an operational diagnosis but not mutation are followed based on family history. Those guidelines 
are listed below: 
 
 
  19 
Women 
► Breast 
- Awareness starting at age 18 years 
- Clinical breast exam, every 6-12 months starting at age 25 years or 5-10 years 
before the earliest known breast cancer in the family 
- Annual mammography and breast MRI screening starting at age 30-35 years or 
based on earliest age of onset in the family 
- Consider risk-reducing mastectomy 
 Includes counseling regarding degree of protection, extent of cancer risk, 
and reconstruction options 
 Address psychosocial, social, and quality of life aspects 
► Endometrial 
- Patient education and prompt response to symptoms 
- Consider annual random endometrial biopsies and/or ultrasound beginning at age 
30-35 years 
- Risk-reducing hysterectomy (discussion same as mastectomy) 
Men and Women 
► Annual comprehensive physical exam starting at age 18 years or 5 years before the 
youngest age of diagnosis of an associated cancer in the family (whichever comes first) 
► Thyroid 
- Particular attention to thyroid exam during physical 
- Ultrasound starting at age 18 years or 5-10 years before earliest known thyroid 
cancer in family (whichever is earlier) 
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► Colon 
- Colonoscopy, starting at age 35 years, every 5 years or more frequent if patient is 
symptomatic or polyps found 
- Consider renal ultrasound starting at age 40 years then every 1-2 years 
► Consider psychomotor assessment in children at diagnosis and brain MRI if there are 
symptoms 
► Education regarding signs and symptoms of cancer 
Risk to Relatives 
► Advise about possible inherited cancer risk to relatives, options for risk assessment, and 
management 
► Recommend genetic counseling and consideration of genetic testing for at-risk relatives 
1.1.5 Genetic Counseling 
Cancer genetic counseling in general is geared to identify individuals with cancer predisposition 
gene mutations as well as those family and personal histories that affect the overall risk for 
development of cancer. However, only about 7-10% of cancers are associated with heritable 
conditions, leaving a majority of individuals left without a single gene cause. Cancer genetic 
counseling has become an imperative part of the risk assessment process in order to identify 
those with mutations in cancer genes as well as to reassure those who have not inherited a 
specific mutation but may still be at increased risk for developing malignancies. 
Counselors can us a variety of qualitative and quantitative risk assessments to determine 
an individual’s risk for possessing a deleterious mutation in a cancer gene and for developing 
cancer. Qualitative risk assessment primarily uses family and personal medical histories to 
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determine an individual’s risk, and incorporates environmental factors, such as toxic substances, 
use of medications, and lifestyle issues. An accurate assessment includes a detailed personal and 
family history, including, but not limited to, age of patient and family members, reproductive 
history, causes of death, lifestyle issues, such as obesity and oral contraceptive use, age and type 
of cancer diagnosis, and years of survival. Quantitative risk assessment uses risk assessment 
models to determine an individual’s risk to carry a deleterious mutation. Most models are geared 
toward assessing risk for breast cancer, so the combination of qualitative and quantitative 
assessment is necessary. 
To date, there are only two risk assessment tools for Cowden syndrome, the Cleveland 
Clinic PTEN calculator and the Ohio State University calculator. The Cleveland Clinic risk 
assessment tool is based on the patient’s medical history and physical findings. It has been 
shown to outperform the NCCN Cowden testing criteria.18 It was developed from a prospective 
series of 3,042 probands who, at minimum, met the relaxed Consortium diagnostic criteria. After 
comparing age-related prevalence within mutation positive and negative participants to expected 
community frequencies from published literature, a weighted score was given for each studied 
phenotype. The weight was adjusted where referral bias was evident, mostly for cancer 
diagnoses, and then totaled to calculate a total PTEN risk score. This score correlates with 
percent risk for finding a germline PTEN mutation. The tool was developed with the thought that 
it would be easy to use for clinicians who would be able to inquire about the different features 
from the checklist provided. 
The Ohio State University is home to the primary clinical laboratory in the United States 
to offer PTEN gene testing, having tested the most patients. Because of this, they were able to 
assemble the world’s largest reported series of clinically tested, mutation positive patients (802 
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subjects) on which to assess clinical features and performance of the Consortium criteria.17 
Besides determining the prevalence of the phenotypic features of Cowden syndrome in the 
cohort (discussed in a previous section), a model was developed to predict the likelihood of a 
PTEN mutation for a patient based on their clinical features. It was also determined that the 
Consortium criteria is not as robust at identifying patients with mutations as previously thought, 
due to the fact that only 34% of subjects meeting the criteria had a detectable mutation, which is 
significantly lower than the 80% previously reported.47 
Psychosocial assessment is also important during the counseling process since individuals 
frequently face emotional stress and psychological upset based on the findings of counseling 
and/or genetic testing. It is pertinent to obtain information from individuals before counseling 
and risk assessment concerning their expectations for the counseling session, the personal impact 
of the cancer in question, the potential clinical outcomes, their relationship with relatives, the 
desire to initiate preventative measures in case an increased risk for cancer is determined, and the 
personal and familial implications of a positive or negative genetic test result. This information is 
important to consider so counselors are aware of and work with these issues so they can provide 
effective counseling and empower their patients to obtain all the information in order to make the 
best decision for them. 
1.2 SPECIFIC AIMS 
A topic that has not yet been explored is the question of implementing head circumference 
measurement in a cancer genetic counseling session. Head circumference growth charts are 
presumably used on a daily basis in a pediatric setting, at least in a clinical genetics department, 
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but the implementation of head circumference measurement in an adult setting is not well 
understood, especially in a cancer genetics consultation. If head circumference is measured in a 
clinical cancer genetics consultation, the question of how this decision was made is also an area 
of interest since once again, it is not well studied. These questions will attempt to be answered by 
implementing specific aims to facilitate assessment of genetic counselors’ attitudes towards head 
circumference measurement. 
1.2.1 Specific Aim 1 
Specific Aim:  To determine whether head circumference is currently being measured clinically 
in hereditary cancer assessment 
Hypotheses:  Head circumference is not being measured for every patient who presents for 
hereditary cancer assessment. 
Half of the patients who present for hereditary breast cancer assessment will 
receive a head circumference measurement. 
1.2.2 Specific Aim 2 
Specific Aim:  To assess the attitudes of genetic counselors concerning the clinical 
implementation of head circumference measurement for any patient with a 
Cowden syndrome associated cancer. 
Hypotheses:  Most counselors will use a variety of techniques to determine which patients 
should receive head circumference measurement and information on other clinical 
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symptoms is also elicited with all patients who present for cancer genetic 
counseling. 
 Half of the genetic counselors surveyed will believe head circumference 
measurement is a beneficial tool for all patients and the other half will not think it 
is necessary for all patients. 
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2.0  EXPERIMENTAL DESIGN AND METHODS 
2.1 PARTICIPANTS 
Study participants were recruited through an e-blast maintained by the National Society of 
Genetic Counselors (NSGC), including dissemination to all members, including full, associate, 
and student members. The invitation to participate (Appendix C) and the electronic questionnaire 
(Appendix D) were disbursed to approximately 3,000 members of the NSGC. Approximately 
25%, or 740 individuals, of these members are thought to specialize in cancer genetics. However, 
it is assumed that not every practicing cancer genetic counselor is a member of the NSGC. 
Therefore, the target sample size was 250 individuals but the actual number of participants was 
216. The participants were both male and female and of all ethnic backgrounds. All participants 
were over the age 18 years. The participants were not mentally incompetent or members of any 
other legally restricted group. The participants were reminded that the questionnaire is 
completely voluntary and can choose to stop participation at any point. All participants who 
completed the questionnaire had the option to enter a random drawing for a $25 Amazon gift 
card donated by the study investigators. Contact information for the drawing was entered 
separately from the study using an option at the end of the questionnaire by providing the email 
address of the co-investigators. If participants elected to be entered for the drawing, they sent an 
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email to the co-investigator with their name and email address in order to be contacted if they are 
the winner of the drawing. 
2.2 QUESTIONNAIRE 
The questionnaire used for this study was created by the co-investigators at the University of 
Pittsburgh and Allegheny Health Network, and approved for research purposes by the 
Institutional Review Boards of the University of Pittsburgh and Allegheny Singer Research 
Institute (ASRI) in Pittsburgh, Pennsylvania (see Appendices A and B for approval). The 
questionnaire, designed through Qualtrics, included 14 multiple choice and short answer 
questions for the participants. The first six questions pertained to the participant demographic 
information in order to determine the details of the study population. These included questions 
such as gender, age range, number of years practicing cancer genetic counseling, and primary 
credentials. The last eight questions were designed based on the review of current literature and 
the specific aims of this study. These questions include current clinical practices and beliefs 
about the clinical readiness of head circumference measurement. Multiple opportunities existed 
throughout the questionnaire for participants to elaborate on their answers and provide personal 
comments. The open-ended questions were also taken into consideration during data analysis, as 
described below. 
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2.3 DATA COLLECTION  
Data was collected in April and May of 2014. The questionnaire took approximately ten minutes 
to complete. Data from a total of 216 participant questionnaires was used for analysis. All 
participants were contacted two weeks after the initial e-blast was sent, whether they completed 
the questionnaire or not, as a reminder for their voluntary participation in this study. Information 
was gathered on the participants demographic information, including gender, age range, 
credentials, and number of years providing cancer genetic counseling. Information was also 
collected about the current clinical practices and beliefs about head circumference measurement, 
which included multiple choice and short answer responses. All of this information was obtained 
through Qualtrics Survey Software, a system that allows results to be read in real-time, analyzed, 
and presented in a user-friendly fashion. A user ID and password were required to access the 
data. 
2.4 DATA ANALYSIS 
2.4.1 Descriptive Statistics 
The results of this study were analyzed using descriptive statistics, qualitative data interpretation, 
and thematic analysis. The descriptive statistics method was used because it is a quick way to 
display and interpret the data. Because there were several demographic and multiple choice 
questions, this is the best mode of analysis to use. This method allows researchers to notice 
trends, if any, which may warrant a more detailed look for future research studies. Data was 
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collected and quantified to evaluate individual question trends or overall trends with multiple 
questions. For both specific aims, a Z test for proportions was used in order to determine if the 
results were different than half, or 50%. This was also used to determine the difference between 
the current practices and beliefs of the participating counselors. Because this is a preliminary 
study, the data analysis aimed to summarize the results for an information-gathering study. 
2.4.2 Qualitative Data 
Qualitative research aims to study from the perspective of the acting individual by applying 
interpretive and naturalistic approach to its subject matter.59 Qualitative research aims to capture 
the empirical reality of social life, meaning researchers much give careful attention to the range 
of contextual issues and the variety of perspectives that exist in society. This type of description 
is usually gathered from minimally to moderately open ended questions, as is the case for this 
study. It can be effective in obtaining and understanding how various perspectives create and 
sustain particular understandings of empirical reality. However, collection and analysis of 
qualitative data is typically more time consuming, labor intensive, and intimate as compared to 
quantitative data collection and analysis. Analysis of qualitative data is a dynamic process and is 
data-derived by generating themes in the course of the study. This methodology is a large part of 
this study in order to determine the beliefs of genetic counselors towards head circumference 
measurement.  
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2.4.3 Thematic Analysis 
Analysis of the qualitative data involves the identification, analysis, and reporting of patterns, or 
themes, within the data. A theme is defined as a pattern that captures something important about 
the data in relation to the research question and represents some level of meaning within the data 
set. Detecting these themes involves a process of coding and interpreting the data. The thematic 
analysis used in this study was conducted in an inductive manner by coding the data without any 
preconceived ideas devised by the investigators. On the other hand, theoretical thematic analysis 
involves a more explicitly analyst-driven approach and provides a more detailed analysis of 
some aspect of the data in contrast to a less rich description of the data overall. 
Data from the open-ended responses in the electronic questionnaire were exported to 
Microsoft Excel. Thematic analysis was used to analyze the open-ended response data using 
guidelines proposed by University of Wisconsin Planning Council for Health and Human 










  30 
Table 2. Phases of Thematic Analysis 
Phase Description of Process 
Read through all responses 
Reading through all the responses will enable a sense of emerging 
themes 
Develop categories 
Develop categories to include the themes that emerged during 
initial review 
Assign each response to a 
category 
Known as coding, each response will be assigned a category or 
categories 
Check your categories 
Check to see if categories are actually appropriate. Some 
categories may be broken into subcategories. 
Review for major themes 
Review to see which categories have the most responses and 
therefore represent major themes. Think about what the themes 
are really saying. 
Identify patterns and trends 
Identify which categories are related and where patterns and 
trends can be identified 
Write-up analysis 
Summarize in order effectively communicate the findings. Use 
descriptive text incorporating some of the comments that 
exemplify major themes. Themes may complement or clarify the 
quantitative data to tie it all together. 
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3.0  RESULTS 
3.1 DEMOGRAPHICS 
A total of 216 NSGC members participated in this study. Only data from those who have 
practiced cancer genetic counseling in the last six months were used. A majority of the 
participants were female (94%) and aged 21 to 30 years (50%). Most individuals (62%) 
identified their primary credentials as having a Master’s of Science (MS) in Genetic Counseling 
and being a Certified and/or Licensed Genetic Counselor (CGC/LGC). It is assumed that those 
who stated only CGC/LGC (25%) also have a MS in Genetic Counseling. It is also assumed that 
those who stated as only having a MS in Genetic Counseling (10%) have not taken the 
Certification Exam or they practice in a state that does not require licensure. A majority of the 
participants have been practicing cancer genetic counseling for one to five years (60%), as well 
as work in a primary clinical counseling work setting (98%). Table 3 illustrates the full 
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Table 3. Questionnaire Demographics 


























MS in Genetic Counseling Only 
CGC/LGC Only 
MS in Genetic Counseling + CGC/LGC 
MS in GC, CGC/LGC, other* 







































*Those who chose other stated their primary credentials as: 
1. CCGC (Canadian) 
2. Also have other Master’s degree 
3. Credentialed Advance Practice Nurse Genetics (APNG) 
4. 2nd year genetic counseling student 
5. MPH genetic counselor 
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3.2 SPECIFIC AIM 1 
Specific aim 1 was designed to determine whether head circumference is currently being 
measured in a clinical setting. Certain questions were developed in order to provide information 
for this aim, specifically questions seven, eight, and nine (see Appendix D). Both descriptive 
statistics and qualitative data analysis were employed to determine whether head circumference 
is currently being measured.  
3.2.1 Descriptive Statistics 
Study participants were asked if they measure the head circumference on every patient that 
presents for a hereditary cancer genetics assessment and also if they measure on every patient 
that presents for a hereditary breast cancer assessment. Both questions were asked in a ‘yes or 
no’ fashion, with an opportunity to elaborate following the question. If a participant answered 
‘yes’ to measuring on all individuals who present for hereditary cancer assessment, another 
question was asked. This question was asked in order to determine if the reason for the head 
circumference measurement being taken was explained to the patient. The results are displayed 
in Figure 1. As seen in this figure, the majority of participants for questions seven and nine 
answered ‘no’, they do not measure on every patient and/or every breast cancer who presents for 
hereditary cancer assessment. However, there were six individuals who do not measure on every 
patient but explained that this is part of routine clinical care for their patients. These participants 
do not personally measure, but the nurses or oncologists in the clinic will. It is also noted that, in 
the majority of cases, if head circumference is measured, an explanation is given to the patient. 
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Figure 1. Head circumference measurement on all and breast cancer patients 
The questions state: 
Question 7: Do you measure head circumference on every patient who presents for cancer genetic 
counseling? 
Question 8: Since you do measure head circumference on every patient, do you explain to them why you 
take this measurement? 
Question 9: Do you measure head circumference on every patient with breast cancer who presents for cancer 
genetic counseling? 
3.2.2 Narrative Responses 
Questions seven and eight were designed to assess Specific Aim 1 by including open-ended 
responses to elaborate why the participant chose their answer. Thematic analysis was used in 
order to analyze the qualitative data from the responses. Out of the 214 individuals who 
answered question seven, 192 gave an open-ended response. Although not all respondents who 
answered the question gave a narrative response, 90% did answer which allowed the thematic 
analysis to occur. For the 32 individuals who measure head circumference on everyone, 27 gave 
an open-ended response. 
  35 
3.2.2.1 Head circumference measurement on all individuals 
Participants were asked in a free response format to explain how their clinic made the decision to 
measure or not to measure head circumference on all individuals who present for hereditary 
cancer assessment. After reviewing all responses, each response was arranged into a category 
and coded to determine the major themes that arose from this question. Table 4 provides the 
themes identified within the responses. 
Table 4. Themes derived from Question 7 
Category # Theme from Analysis Number of Participants 
1 Suspicious of Cowden syndrome1 120 
2 Routine in clinical care or based in a pediatric setting 9 
3 
Measurement on everyone unless individual is coming 
in specifically for a non-PTEN site-specific testing2 5 
4 
No formal decision has been made or it has been that 
way since starting at the clinic 
22 
5 
Feel that it is not part of the training for genetic 
counselors or the measurement is used solely as an 
estimate 
8 
 Multiple themes involved 23 
1Includes cancers and/or features of Cowden syndrome elicited from family and/or personal 
history 
2For example, BRCA1/2 genetic testing 
 
 The theme with the most amounts of responses was category one, ‘Suspicious of Cowden 
syndrome’. Counselors felt that a suspicion of Cowden syndrome included one or more cancer(s) 
and/or other benign findings associated with the condition in the family and/or personal history 
of the patient. One participant wrote in regard to only measuring when suspicious of Cowden 
syndrome: 
We base this off of reported personal and family history – if there is any indication of Cowden 
syndrome in the patient or family members, we’ll take a head circumference to document on the 
family history and to see if they do in fact, meet criteria for PTEN testing 
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Another commented:  
We measure based on family history…if it is suggestive of a PTEN mutation, we will measure. 
This decision was made based on the clinical presentation of typical PTEN mutations 
One other participant stated: 
I take OFC’s on patients with a personal history of cancers associated with PTEN (breast, CRC, 
renal) 
Another theme involved several individuals feeling it was outside the scope of practice for 
genetic counselors to be measuring head circumference. Some measure head circumference but it 
is only used as an estimated measurement. A participant commented: 
I do not feel qualified to take an accurate head circumference 
There were also individuals who had the opposite opinion and thought head circumference 
should be measured on everyone, unless the individual was specifically presenting for non-PTEN 
genetic testing, such as BRCA1/2. One participant stated: 
I do not measure OFC only for patients who are presenting for non-PTEN site-specific testing. 
Everyone else gets a head measurement.  
Along the same beliefs, another participant stated: 
We had multiple patients that had negative BRCA1/2 testing and we were considering PTEN and 
kicking ourselves that we didn’t have a head circumference so we started measuring it for all 
patients seen at our institution. 
There were also individuals who work in a setting where head circumference measurement is 
routine in clinical care, in addition to weight, height, and blood pressure, and may also include 
working in a pediatric setting. In these cases, a nurse would measure the head circumference, not 
the genetic counselor. One individual noted that: 
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It is part of their physical evaluation along with weight, height, and blood pressure. I think it was 
originally for the purpose of assessing candidates for PTEN testing. 
A select few individuals work in a pediatric setting but have counseled for hereditary cancer 
assessment. The practices in this case were similar to those who measure due to routine clinical 
care, stating: 
I see only pediatric patients and if they present with adenomatous colon polyps, I do not measure 
an OFC. For almost any other type of polyp, especially hamartoma or juvenile, I do recommend 
an OFC. 
The rest of the individuals who gave a response simply stated that there was no formal decision 
or the decision was made before they started working at the clinic. A participant stated: 
I joined an established clinic where it wasn’t standard to measure head circumference 
Only a few participants brought up the subject of panel testing, which most often includes PTEN, 
and ordering the testing for those who present for hereditary cancer assessment. They felt it was 
unnecessary to measure head circumference when ordering a panel. In particular, one participant 
commented: 
For my patient that we suspect PTEN, we will order a NGS panel that includes PTEN analysis. 
The only time head circumference is measured is if PTEN alone is suspected, and there is no 
panel that the patient would be eligible for that includes PTEN and PTEN analysis only is going 
to be pursued 
Others, however, felt that measuring head circumference, in addition to ordering a panel, was the 
best approach for their clinic. One participant stated: 
It was fairly common practice prior if there was a suspicion of Cowden syndrome. Since the 
advent of panel testing it was decided that it should be routine for all patients 
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Some of the responses from the participants encompassed multiple themes, most of which 
identified measuring when suspicious of Cowden syndrome, plus another theme. Examples of 
the multiple themes expressed are described in Table 5. 
Table 5. Multiple themes expressed in a single statement 
Category # Statement 
1 & 4 
No formal decision has been made. I measure a patient’s head circumference when 
Cowden syndrome is a concern based upon personal or family history information, 
and only when the patient consents. We do not have a medical geneticist and so I ask 
patients before doing that measurement. 
1 & 5 
We measure heads when there is a suspicion of Cowden syndrome. Also, we don’t 
always have an Medical Geneticist in clinic to do this and I’m not confident about all 
my measurements. 
2 & 3 
Our clinic began as primarily pediatric/general genetics and over the years has 
expanded to include cancer genetics. Measuring head circumference has always been 
a requirement for our general genetics patients; therefore it is now a requirement for 
all cancer genetics patients. As we have expanded our program to include off-site 
cancer specific clinics, those patients also received head circumference measurement 
as this is a helpful measurement for PTEN risk assessment 
 
All of the participants who responded with an open-ended comment fell into at least one of the 
themes described above.  
3.2.2.2 Explanation of Head Circumference Measurement 
Participants were asked in a free response format to describe why or why not an explanation is 
given to patients as to why head circumference measurement is taken. After reviewing all 
responses, each response was put into a category and coded to determine the major themes that 




Table 6. Themes derived from Question 8 
Category # Theme from Analysis Number of Participants 
1 




Nurses do the measuring as part of routine clinical 
care 
1 
3 Explain only if the patient asks 3 
4 Explain everyone gets the measurement done 2 
Multiple themes involved 5 
A majority of the participants commented that they do explain to a patient why the measurement 
was taken and explain that large head size is associated with a cancer syndrome. One participant 
responded: 
I give a very brief explanation that occasionally a feature of a hereditary cancer syndrome is a 
larger head size. I only elaborate if the patient asks. 
Another participant commented: 
I’ve noticed that patients are more accepting if they understand why questions or measurements 
are being taken. It helps them to feel a part of the process. 
Some have a different approach and explain that all patients have their head circumference 
measured as part of their assessment. A participant stated: 
We explain that as part of a genetic evaluation we often take many measurements. 
In other clinics, the nurses do the measuring as part of routine clinical care, which is explained to 
the patient, either by the nurses or the genetic counselors if the patient asks. One participant 
responded to this decision by stating: 
I do not do the measurement myself. I have told the medical assistants that if a patient asks, they 
should tell them that it is done on all patients coming for genetic counseling since sometimes the 
genetic counselor uses the measurement in her assessment. 
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The respondents who answered ‘no’ to this question all fell into the theme that an explanation is 
given only if the patient asks. One participant stated: 
Only if they ask or if we are suspicious of PTEN mutations. 
All of the responses were clear and fit into only one theme. No overlapping of themes was 
included in any of the responses. 
3.3 SPECIFIC AIM 2 
Specific aim 2 was designed to assess the attitudes of genetic counselors concerning the clinical 
implementation of head circumference measurement for any patient with a Cowden syndrome 
associated cancer. The rest of the questions in the questionnaire were directed at answering this 
aim (see Appendix D). Some of the questions were skipped if a certain answer was chosen and 
was designed this way on purpose. For example, if the answer to question nine was ‘yes’, 
question ten would be skipped. If the answer to question 11 was ‘no’, question 12 was skipped. 
This mechanism was built into the survey so if a question was skipped, the respondent did not 
see the question nor have the chance to answer. Both descriptive statistics and qualitative data 
analysis were employed to determine the beliefs of genetic counselors in implementing head 
circumference measurement. 
3.3.1 Descriptive Statistics 
Study participants were asked about their beliefs on implementing head circumference 
measurement on all patients who present for hereditary cancer assessment. The questions 
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directed at these beliefs were either asked in a ‘yes/no’ or multiple choice fashion. Question 13 
enabled participants to elaborate on their answer. If a participant answered ‘no’ to question nine, 
they were given the option to answer question 10. Of the 163 people who answered ‘no’ to 
question nine, 160 responded to question 10. Question 10 had the option for ‘other’ to be 
selected, in which the participant was asked to specify why they chose that answer. 
Unfortunately, question 10 did not give the option to select multiple choices so the ‘other’ 
category included some or all of the choices. Because of this, it was easy to categorize these 
responses, similar to the thematic analysis, and to incorporate multiple answers instead of just 
one. Figure 2 displays the multiple choice answers. The legend signifies how many participants 
chose just one answer or how many times participants included a choice. For example, nine 
participants chose A, but choice A was selected 25 times in conjunction with choices B, C, D, 
and/or E. Most respondents would have chosen all of the above and taken multiple factors into 
consideration when deciding which patients should have their head circumference obtained. 
Figure 2.Reasons for determining when to measure head circumference
The question states: Since you do not measure head circumference on every patient, how do you determine 
which patients should have their head measured? 
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The next set of questions aimed to determine if genetic counselors elicit information on 
other clinical symptoms of Cowden syndrome with every patient, and if so, how they elicit the 
information. Figure 3 shows that just over half of genetic counselors elicit information on other 
clinical symptoms of Cowden syndrome with every patient who presents for counseling. Of the 
counselors who do, Figure 4 shows that most counselors elicit information from review of 
systems questions, directed questions about Cowden syndrome, and from medical records. Most 
other counselors are eliciting information from directed questions about Cowden syndrome only, 
or review of systems questions and directed questions or medical records. 
Figure 3. Eliciting information on other clinical features of Cowden syndrome  
The question states: Do you elicit information on other clinical symptoms of Cowden syndrome with every 
patient who presents for cancer genetic counseling? 
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Figure 4. How information is elicited about Cowden syndrome 
The next question aimed to decipher the professional opinions of counselors to determine 
if they believe head circumference should be measured for every patient who presents for cancer 
counseling. As shown in Figure 5, a majority of the counselors believe head circumference 
should not be measured in every patient, but should be reserved only for those that are suspicious 
of Cowden syndrome. 
 
Figure 5. Should head circumference be measured on every patient 
The last questioned aimed to also decipher the professional opinions of the counselors to 
determine the percentage of cases they feel are undiagnosed due to head circumference not being 
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measured. Figure 6 shows that 31% of counselors believe between one and two percent of 
Cowden syndrome cases are undiagnosed while 18% believe more than 5% are missed.  
 
Figure 6. Percentage of Cowden syndrome cases believed to be undiagnosed 
3.3.2 Narrative Responses 
Question 13 was designed to assess Specific Aim 2 by including an open-ended response to 
elaborate why the respondent chose their answer. Thematic analysis was used in order to analyze 
the qualitative data from the responses. Out of the 216 individuals who answered the question, 
209 gave an open-ended response. Although not all respondents who answered the question gave 
a narrative response, 87% did which allowed for the thematic analysis. 
Participants were asked in a free response format to explain why they believe head 
circumference should be measured for every patient who presents for hereditary cancer 
assessment or why they do not believe this should be standard practice.  After reviewing all 
responses, each response was put into a category and coded to determine the major themes that 
arose from this question. Table 7 provides the themes identified within the responses. 
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Table 7. Themes derived from Question 13 
Category # Theme from Analysis Number of Participants 
1 
Cowden syndrome is rare and likely not 
helpful in assessment 
44 
2 Only if suspicious of Cowden syndrome 73 
3 Easy measurement to help in assessment 12 
4 
Good clinical practice and/or essential in 
assessment 
29 
5 Moving towards panels so it is not necessary 7 
 Multiple themes involved 12 
 
The theme with the most amounts of responses was category two, ‘Only if suspicious of 
Cowden syndrome’. One participant wrote in regard to the clinical practice of only measuring 
head circumference on those that are suspicious of Cowden syndrome: 
Anyone with a remote chance of Cowden in the differential should have their head 
circumference measured. I suppose you could do it on everyone, but I don’t think it is necessary 
Another participant noted: 
I think it is best to measure OFC in patients who seem Cowden-like. If I am seeing a woman for 
a history of breast and ovarian cancer, a large head circumference will not change my decision 
to pursue BRCA testing first (in the absence of other Cowden-related symptoms in the patient’s 
personal or family history) 
While most identified with only measuring when there is a suspicion for Cowden syndrome, the 
next largest group of participants believed that Cowden syndrome is rare so measuring head 
circumference on all patients would not necessarily be helpful. One participant commented: 
Although I understand our incidence may be underestimated, it is still rare, and it is not 
necessary on every patient. 
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On the other hand, other counselors believed it is good clinical practice to measure head 
circumference on all patients and/or is essential in hereditary cancer assessment. One participant 
believes that: 
Macrocephaly is considered a major criterion for Cowden syndrome, and many times the other 
features can be subtle or considered “common” (i.e. fibrocystic breasts, uterine fibroids, thyroid 
problems), therefore it is my professional opinion that measuring head circumference for every 
patient who presents for cancer genetic counseling is good clinical practice and an essential part 
of the cancer genetics evaluation. 
Another participant responded in such a way because of a particular patient, stating: 
You may not know if a patient meets criteria for PTEN testing without doing so. I actually had 
one patient that was identified as having a PTEN mutation only because I made a point to 
measure every breast cancer patient’s head. Otherwise, this would not have been known. 
Similarly to the respondents above, other participants thought measuring head circumference is 
quick and easy and can aid in hereditary cancer assessment. One participant responded: 
It’s an easy, quick thing to do. Typically there are other things in addition to macrocephaly that 
make us think about PTEN testing but why not, more information is better 
The last category involved genetic counselors believing cancer genetic testing is moving towards 
panels and not individual PTEN testing. Some felt that measuring head circumference may not 
be necessary in this case since the genetic testing includes PTEN, the only gene associated with 
Cowden syndrome. One participant wrote: 
Since we are shifting more towards panel testing each year, I think PTEN will be performed on 
many more patients, and head circumference will not necessarily be a determining factor. 
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A few counselors’ comments encompassed more than one category. Although there were very 
few comments like this, a few interesting examples are noted. One participant encompassed the 
rarity of Cowden syndrome, measuring when there is a suspicion, and head circumference being 
an easy measurement with the statement:  
Cowden syndrome is rare, and most patients, even with associated features do not have this 
condition. Macrocephaly should only be evaluated for if other Cowden syndrome features are 
present. However, since it is a fairly simple and non-invasive procedure, I don’t feel strongly 
that it shouldn’t be done, just that it’s not necessary. 
Another participant encompassed measuring when there is a suspicion and panel testing by 
stating:  
That was usually reserved for suspicion of Cowden cases, however with the new cancer panels, 
and “surprising” result, maybe obtaining head circumference would not be a bad idea for 
clinical correlation. 
Another participant encompassed head circumference measurement as good clinical practice as 
well as panel testing by commenting:  
Cowden syndrome is underdiagnosed and with the advent of panel testing I think we are also 
going to start seeing broader phenotypes so it will be helpful to have as much information as 
possible to help correlate. 
All of the participants who responded open-endedly fell into at least one of the themes described 
above. 
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4.0  DISCUSSION 
The practices, attitudes, and beliefs of genetic counselors regarding the measurement of head 
circumference for patients who present for hereditary cancer assessment has, to the best of our 
knowledge, not yet been documented in the literature. The goal of this study was to assess these 
practices, attitudes, and beliefs about implementing head circumference measurement in a cancer 
genetic counseling appointment. Specific aims were developed in order to sufficiently explore 
this topic, along with hypotheses for each aim. An aspect of this study that may be different from 
others like it is the fact that it is more of an informational or preliminary study and is the starting 
point for many other studies that will be discussed in this section. The bulk of the analysis came 
from the qualitative data which gave an interesting insight into the attitudes and beliefs of 
genetic counselors on measuring head circumference measurement in hereditary cancer 
assessment. 
4.1 SPECIFIC AIM 1 
Specific Aim 1 was focused to determine whether head circumference is currently being 
measured clinically in a hereditary cancer assessment setting. It is widely accepted that 
macrocephaly is associated with Cowden syndrome, but the exact prevalence is still being 
elucidated, falling somewhere between 50-80%. However, whether health care professionals are 
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measuring head circumference in an oncology setting is unclear. The literature has provided 
essential information on head circumference measurement for Cowden syndrome, including 
diagnostic and genetic testing criteria, but this study was intended to determine if and how those 
guidelines are being followed. Centered on this specific aim, hypotheses were formed based on 
the literature. 
The results for specific aim 1 were obtained and analyzed through descriptive statistics, 
qualitative data, and thematic analysis. A majority of the counselors (85%, see Figure 1) are not 
measuring on every patient, but their reasons for doing so were also analyzed. These results are 
consistent with the first hypothesis, that head circumference is not being measured for every 
patient who presents for hereditary cancer assessment. This is not a surprising result given the 
fact that the only cancer syndrome associated with macrocephaly is Cowden syndrome.  
There were several themes that developed through the narrative responses to the question 
of measuring head circumference on every patient. As noted before, a majority of genetic 
counselors stated that their clinic, whether it is a group of individuals, one or two people, or just 
themselves, decided to only measure head circumference on those patients that were suspicious 
of Cowden syndrome. Of these counselors, most agreed that they base their judgment off the 
diagnostic and genetic testing criteria guidelines. Despite their reasoning, we can conclude that 
most counselors are not measuring head circumference on every patient, only those who are 
suspicious for Cowden syndrome. Macrocephaly is a major criterion for the diagnosis of Cowden 
syndrome, so it is interesting to note that most genetic counselors are measuring head 
circumference when there is other testing criteria present in an individual or family. Genetic 
counselors rely heavily on the data that is published regarding Cowden syndrome, but those 
guidelines have not been officially updated since 1996. Several changes have been suggested as 
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previously noted so it might be beneficial to review and modify the diagnostic and testing 
criteria. 
An interesting set of responses that arose as a theme was the fact that some genetic 
counselors feel it is outside their scope of practice to measure head circumference on their 
patients. These genetic counselors felt they were not trained or not trained properly to take head 
circumference measurements on patients. Because of these narrative responses, it might be 
beneficial to implement training for genetic counselors so they are able to measure head 
circumference and feel confident in doing so. 
Additional information on head circumference measurement was gathered from those 
individuals who measure on all patients who present for cancer genetic counseling. A majority of 
counselors (84%, see Figure 1) explain to their patients why they are taking the head 
circumference measurement or if the patient asks and the counselors feel it is not necessary to 
explain since it is part of their vitals assessment before the appointment. This is not a surprising 
result since the major role a genetic counselor plays in sessions is giving the patient information 
so they can make the decision that is best for them. In certain situations it may not be beneficial 
to give a patient more information, but giving an explanation for head circumference 
measurement will hopefully limit the confusion as to why this is being done, as well as allow the 
patient to feel satisfied with the information provided. It seems the genetic counselors who 
answered this question appreciate that an explanation is in the best interest of their patients.  
The second hypothesis for specific aim 1 states that half of the patients who present for 
hereditary breast cancer assessment will receive a head circumference measurement. A majority 
of genetic counselors (76%, see Figure 1) are also not measuring on patients who present 
specifically for breast cancer genetic counseling due a personal and/or family history. These 
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results are statistically significant (p-value = 1.63x10-17) and are not consistent with the second 
hypothesis, but it is interesting to note the differences between measuring on all patients and 
measuring on those presenting for breast cancer. Although the majority of counselors are not 
measuring for either group, there are more measuring on those presenting with breast cancer 
(24%, Figure 1) compared to all patients presenting for cancer genetic counseling (15%, Figure 
1). The difference between these two groups could be the fact that breast cancer is a major 
criterion on the list of diagnostic criteria. Because of this, Cowden syndrome may appear more 
on a list of differentials for these patients rather than those who are not presenting specifically for 
hereditary breast cancer assessment.  
4.2 SPECIFIC AIM 2 
Specific Aim 2 was directed to assess the attitudes of genetic counselors concerning the clinical 
implementation of head circumference measurement for any patient with a Cowden syndrome 
associated cancer. After determining that most genetic counselors are not measuring head 
circumference in a clinical setting, unless there is a suspicion for Cowden syndrome, specific aim 
2 allowed us to assess whether genetic counselors believe this should change or not. Asking 
certain questions about their current practices and their professional opinions allowed us to 
obtain results directed at this aim and analyze the hypotheses associated. Centered on this 
specific aim, hypotheses were formed based on the literature. 
The results for specific aim 2 were obtained and analyzed through descriptive statistics, 
qualitative data, and thematic analysis. Those participants that do not measure head 
circumference on all patients were given a list of different ways one might determine which 
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patients should have their head circumference measured. Those results are described completely 
in Figure 2. Most of the participants chose ‘other’ (61%) since they were unable to choose 
multiple determining aspects. This was a flaw in the questionnaire since the question was 
originally designed to allow participants to choose more than one answer, but this did not 
translate to the questionnaire online. However, of the participants that chose ‘other’, new 
categories were created within this option and all participants fell into a single category. Most 
participants chose ‘all of the above’ (46%) which signified they use information from personal 
and family history, as well as macrocephaly to determine when they measure head circumference 
on a patient. The other participants chose two or more options that included A, B, C, D, and/or E, 
which are also described in Figure 2. The participants use a combination of personal and family 
history for Cowden syndrome associated cancers and features. A large part of a cancer genetic 
counselor’s job is to elicit information from the personal and family histories to determine if 
there is a concern for a hereditary cancer syndrome. All counselors surveyed seem to be doing 
just that in assessing who should have their head circumference measured. 
Along this same line, the counselors were asked if they elicit information specifically on 
other clinical symptoms of Cowden syndrome with every patient. More than half (55%) replied 
that they do elicit this information, as shown in Figure 3. The specific aim also sought to 
determine what format counselors are eliciting information, if at all. Participants were able to 
answer with any of combination of the three options given, general review of systems, directed 
questions about Cowden findings in the review of systems, and medical records. Most 
participants (36%) chose all three, that they use the combination of all the resources to elicit 
information specifically about Cowden syndrome. These results were expected since it is thought 
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genetic counselors use all the tools at their disposal to elicit information from their patients in 
order to better assess their situation. 
Based on the above results, we can conclude that genetic counselors use a variety of 
different techniques and questions to determine which patients should have their head 
circumference measured, as well eliciting information on other clinical symptoms associated 
with Cowden syndrome. Although not all counselors use all or the same techniques or questions, 
a majority of the information about head circumference measurement and Cowden syndrome 
symptoms are being elicited for a high percentage of patients. This relates back to the first 
specific aim in that counselors are using the NCCN diagnostic criteria as a guideline for 
gathering information and using their best judgment based on this information. 
The second hypothesis for specific aim 2 states that half of the genetic counselors 
surveyed will feel head circumference measurement is a beneficial tool for all patients and the 
other half will not think it is necessary for all patients. A majority of the counselors (71%, Figure 
5) feel measuring head circumference on every patient who presents for cancer genetic 
counseling should not be standard. This is statistically significant (p-value = 7.62x10-17) and 
although these results are not consistent with hypothesis, the narrative responses obtained give 
insight into why these results occurred. 
There were several themes that developed through the narrative responses about 
measuring head circumference on every patient who presents for cancer genetic counseling. As 
noted before, a majority of genetic counselors stated that the only patients that should have their 
head circumference measured are those in which there is a suspicion for Cowden syndrome, 
exactly what is currently being practiced based on this study. The percentage of counselors 
currently not measuring head circumference on every patient (85%, Figure 1) is slightly different 
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from those who believe head circumference should not be measured on all patients (71%, Figure 
5) and is statistically significant (p-value = 0.00179) It seems that while a majority of those who 
are currently practicing this way also believe it should not be the standard, there are some that 
have opposite practices and beliefs. It is interesting to note this difference because this 
questionnaire may have helped counselors realize what their stance is on measuring head 
circumference, whether it is their current practice to do so or not. Some counselors may not 
currently measure head circumference on every patient, but may reevaluate this decision after 
taking this questionnaire. Although this was not a direct specific aim of this study, it is still 
beneficial for counselors to understand their own practices, attitudes, and beliefs on head 
circumference measurement, as well as others. 
Probably the most interesting theme coming from this question was genetic counselors 
believing every patient should have their head circumference measured because it is good 
clinical practice and/or essential in assessment. This theme is the complete opposite of the 
themes already discussed and shows the diagnostic and genetic testing criteria in a different light. 
When taking all of the comments into consideration, it may be beneficial to begin taking head 
circumference measurements on all patients, or at least those who present for breast cancer 
assessment. It is possible that some individuals with a PTEN mutation may be overlooked 
because their head circumference was not measured. It seems that since this measurement is 
quick, easy, and could be considered another vital along with height and weight, it would be an 
easy way to give each patient the most complete assessment possible. It is something to consider 
and could aid in the detection of a PTEN mutation when one was not originally expected. 
Another interesting theme derived from this question involved panel testing, which is 
becoming more and more relevant in the present day. Most counselors in this category felt that 
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since cancer gene panels are becoming more readily available, head circumference measurement 
will not be a determining factor if PTEN is captured by the panel. In the advent of more cancer 
gene panels, it does seem unnecessary to measure head circumference due to the fact that no 
other information, besides family and personal history, is necessary to order a panel. However, it 
may be beneficial to measure head circumference on those patients who choose to be tested 
through a panel with PTEN coverage in order to better understand the phenotype of Cowden 
syndrome. This relates back to macrocephaly as a major criterion and the incidence associated 
with Cowden syndrome. Macrocephaly has been noted to associated with a majority of cases of 
Cowden syndrome, but this percentage could become higher or lower if we are able to better 
correlate macrocephaly to Cowden syndrome. This could be established by obtaining the head 
circumference on those who choose the cancer gene panel including PTEN.  
The last part of this hypothesis involved asking the professional opinion of the genetic 
counselors to determine what percentage of individuals they believe to be undiagnosed because 
head circumference was not measured. A majority of counselors (61%) felt that either less than 
1% or 1-2% of cases is missed, or undiagnosed, due to head circumference not being measured. 
However, 18% of counselors believe more than 5% of cases are undiagnosed, as shown in Figure 
6. That number is rather surprising given the other results of this study. The current practices, 
attitudes, and beliefs toward measuring head circumference on all patients of most counselors do 
not include obtaining the measurement, but 18% believe more than 5% of Cowden syndrome 
cases are going undiagnosed. Over 5% is a rather high number given the low incidence of 
Cowden syndrome. However, a majority of the counselors (61%) did believe that less than 2% of 
cases are undiagnosed which is expected given the current practices, attitudes, and beliefs. The 
wording of this question may have skewed the results slightly since there was some confusion 
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about what the question was actually asking. Some participants felt there should be a 
clarification to the question since the wording made it seem as if macrocephaly is the only reason 
Cowden syndrome cases are not being diagnosed. If this study is continued in the future, the 
wording of the last question should be more specific by asking “Out of the total number of 
Cowden syndrome cases (diagnosed and undiagnosed), what percentage do you believe to be 
undiagnosed due to head circumference not being measured?”.  
4.3 LIMITATIONS 
The results presented in this study are preliminary and several limitations are present. The first 
limitation comes from the individuals to which the questionnaire was distributed. The individuals 
surveyed were genetic counselors who presumably have similar backgrounds and training. 
Assuming that the genetic counselors represent a relatively homogenous group of people with 
similar backgrounds and training, the results of the study could be biased and difficult to extend 
to other groups, such as oncologists, nurses, or even primary care physicians. It is possible that 
genetic counselors providing cancer risk assessment are measuring/not measuring head 
circumference because this population better understands the features associated with Cowden 
syndrome. Genetic counselors are not the only health care professionals performing hereditary 
cancer assessment. It is possible that other oncology professionals may not fully be aware of the 
features associated with Cowden syndrome and therefore neglect head circumference 
measurement. 
Because online questionnaires are an easy way to obtain information, they are numerous 
studies in the genetic counseling community that implement this study tactic. The individuals 
  57 
contacted for this study may feel there is abundance and therefore choose not to participate. 
Although this particular questionnaire was believe to only take 10-15 minutes to complete, the 
participants may have felt they had an inadequate amount of time to complete another 
questionnaire, and therefore not respond, or not respond completely. This limitation falls under 
the responder-bias term, which is the idea that individuals who did not respond differ from those 
who did respond. The attitudes of the genetic counselors who did respond may differ from those 
who did not. This would result in skewing of the overall results and not be a true representative 
sample. For example, the individuals who responded to the questionnaire may have thought it is 
beneficial to measure head circumference during a hereditary cancer assessment, while those 
who did not respond felt the opposite. This may have occurred for a variety of reasons and would 
be interesting to assess why individuals did not respond, but was not part of this particular study. 
A similar limitation includes the possibility that the same participants responded more 
than once. This could have occurred because all NSGC members were contacted two weeks after 
the questionnaire was distributed as a reminder to complete the questionnaire. Some members 
may have forgotten they participated in the questionnaire when it was first distributed and 
participated again. Unfortunately, there is no way to track this information in the Qualtrics 
survey system.  
There are also limitations that are associated with the questionnaire itself. First, the 
individual questions essentially were arranged in a standard ‘yes’ or ‘no’ answer fashion, with an 
open-ended response or multiple choice question to follow. For the ‘yes’ or ‘no’ questions, all 
asked for a reason (open-ended response) as to why the respondent chose that answer in order to 
better understand the attitudes of the genetic counselors. This enabled the study to incorporate 
qualitative analysis which was a primary goal of this study. However, a participant may have 
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chosen to respond to the initial question, but did not elaborate on his or her response. Therefore, 
this would leave the open-ended response blank, resulting in reduced qualitative analysis and 
potentially an inaccurate portrayal of the results. Some of the multiple choice questions included 
‘other’ in which case the participant was asked to specify their response. Once again, a 
respondent may have chosen this answer, but not specified with an open-ended response. In 
order to eliminate these restrictions in data analysis, the questionnaire through Qualtrics could 
have been set up differently. Instead of giving the respondents an option to fill in the open-ended 
response, the questionnaire would not enable the respondent to move to the next question until an 
answer was given. This would essentially force the participant to answer the open-ended 
question, but may lead to a decrease in the number of participants who fully complete the 
questionnaire. 
4.4 FUTURE STUDIES 
This study is intended to be a stepping stone towards larger studies with different goals. An 
extended recruitment period could enroll more genetic counselors in this study. Extending this 
study to cancer genetic counselors not registered with the National Society of Genetic 
Counselors would increase the number of participants and contribute more to the results already 
obtained in this study. In doing so, a more representative sample would hopefully be achieved.  
Similarly, the questionnaire could be extended to oncologists, nurses, and other health 
professionals who work in an oncology setting. By extending this questionnaire to other 
individuals who work in an oncology setting, a more detailed and robust data analysis could be 
determined. It would be beneficial to determine how other oncology professionals handle 
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measuring head circumference, if at all. The study could then focus on the attitudes of oncology 
health professionals outside of genetic counselors and compare the opinions from the different 
groups in a quantitative and qualitative analysis. 
Another future direction based on this study would include a clinical approach by 
measuring head circumference on patients who present for hereditary cancer assessment. The 
current study would serve as Phase 1 understanding the practices currently employed by genetic 
counselors. The information obtained from other oncology professionals as mentioned before 
could also be considered in the Phase 1 study. The new study, essentially Phase 2, could initially 
be investigated at a select few institutions and then expanded to include several other institutions 
across the country. Measuring head circumference on individuals who come in for cancer risk 
assessment could determine the number of Cowden syndrome individuals, or families, which 
may be missed if head circumference was not measured. This could essentially determine the 
percentage of individuals that would have originally not been offered PTEN genetic testing, but 
would have if macrocephaly was noted during the assessment. Advancing even further with a 
Phase 3 could eventually lead to a proposition to revise the diagnostic or genetic testing criteria 
that the NCCN has employed. 
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5.0  CONCLUSION 
The specific aims of this study were designed to determine whether head circumference is 
currently being measuring clinically in hereditary cancer assessment and to assess the attitudes of 
genetic counselors concerning the clinical implementation of head circumference measurement 
for all patients for hereditary cancer assessment. Overall, most genetic counselors are not 
measuring head circumference on all patients who present for cancer counseling nor those who 
are presenting for breast cancer assessment. However, if the measurement is taken on patients, an 
explanation is given. Most genetic counselors are eliciting information on Cowden syndrome in a 
variety of ways, but most do not feel head circumference measurement should be standard for 
every patient. Most feel only those patients who are suspicious for Cowden syndrome based on 
other clinical features should have their head circumference measured. This study gathered much 
insight into the practices of genetic counselors on this particular topic and may be the initial 
information to creating a more uniform process for measuring head circumference in hereditary 
cancer assessment. 
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APPENDIX C 
INVITATION FOR PARTICIPATION 
Dear Genetic Counselor, 
 
You are invited to participate in an anonymous online survey investigating the current practices 
of genetic counselors regarding head circumference measurement in hereditary cancer 
assessment. You were selected as a possible participant because you are registered in the NSGC 
Familial Cancer Risk Counseling SIG or follow the general NSGC discussion board. This survey 
is part of an ASRI-WPAHS and University of Pittsburgh Institutional Review Board approved 
research project titled,  
Assessing the practices of genetic counselors regarding head circumference measurement in 
hereditary cancer assessment 
 
We ask that you read the following information and contact us with any questions you have 
before beginning the survey. 
If you agree to participate in this study, we would ask you to do the following: 
• Complete the online survey about your current experience as a genetic counselor 
• To connect to the survey, please click on this link: 
https://pitt.co1.qualtrics.com/SE/?SID=SV_4UWZ7Tbs9z5S46N  
Participants will have the option to enter a draw to win a $25 Amazon gift card upon 
completion of the survey. 
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Participation in this research project is completely voluntary. We estimate that the survey will 
take 10-15 minutes to complete. Answers to all of the provided questions would be greatly 
appreciated; however, you may choose to not answer any question(s) within the survey. If you 
decide to participate, you have the right to withdraw at any time. It will not be possible to 
connect any response to any one participant. The records of this study will be kept private. In any 
report that we might publish, any information that will allow for identification of you as a 
participant will not be included. Research records will be stored securely and only researchers of 
this study will have access to the records. There are no identifiers and data will be stored on a 
password protected computer. 
 
Contacts and Questions: 
If you have any questions about the research study, please contact Amanda Matchette 
(asb102@pitt.edu) or Emily James (ejames@wpahs.org or 412-359-8254). 
 
If you would like to talk to someone other than the researchers, you may want to contact the 
ASRI-WPAHS (412-359-3156) or University of Pittsburgh (412-383-1480) Institutional Review 
Boards. 
 
Thank you for your time and consideration. 
 
To connect to the survey, please click this link: 
https://pitt.co1.qualtrics.com/SE/?SID=SV_4UWZ7Tbs9z5S46N  
 
















3. What are your primary credentials? (multiple selections) 
MS (genetic counselor) 
CGC (certified genetic counselor)/LGC (licensed genetic counselor) 
MD (board certified in genetics) 
MD (non-geneticist) 
Genetics Clinical Nurse 
Advanced Practice Nurse 
Other (please specify) ___________________ 
 
4. How many years have you provided cancer risk assessment and counseling? (select 
one) 
1-5 






5. Have you provided cancer risk assessment and counseling in the last 6 months? 
Yes 
No 
(If no – survey stops) 
 
6. Which of the following describes your primary work setting (spend >50% of your 
time)? (select one) 
Clinical counseling 









(If no, skip question 8) 
 




8. If you do measure head circumference on every patient, do you explain to them why 




Please explain why you answered YES or NO. 
(Open-ended question) 
 
9. Do you measure the head circumference on every patient with breast cancer who 
presents for cancer genetic counseling? 
  69 
Yes 
No 
(If yes – skip question 10) 
 
10. If you do not measure the head circumference on every patient, how do you 
determine which patients should have their head measured? (select one) 
Personal history of Cowden syndrome associated cancer 
Personal history of other clinical symptoms of Cowden syndrome 
Family history of Cowden syndrome associated cancer 
Family history of other clinical symptoms of Cowden syndrome 
Appears to have macrocephaly or reports macrocephaly 
Other (please specify) _____________ 
 
11. Do you elicit information on other clinical symptoms of Cowden syndrome with 
every patient who presents for cancer genetic counseling? 
Yes 
No 
(If no – skip question 12) 
 
12. How do you elicit information on other clinical symptoms of Cowden syndrome? 
(select one) 
General Review of systems 
Directed questions about Cowden findings in review of systems 
Medical records from previous centers/institutions 
 
13. In your professional opinion, should head circumference be measured in every 




Please explain why you answered YES or NO. 
(Open-ended question) 
 
14. In your professional opinion, how many cases of Cowden syndrome are 
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